FURTHER OPTIMIZING 2ND GENERATION DUAL-TARGETED FINE-TUNED IMMUNE-RESTORING (DFIR) CAR T CELLS TO ACHIEVE CURES OF ADVANCED CCRCC.
$979,875FY2021Defense Health AgencyDOD
Dana-Farber Cancer Institute, Inc.
Investigators
View source on USAspending →FURTHER OPTIMIZING 2ND GENERATION DUAL-TARGETED FINE-TUNED IMMUNE-RESTORING (DFIR) CAR T CELLS TO ACHIEVE CURES OF ADVANCED CCRCC. · GrantIndex